Angiomyolipoma (AML) — a benign fatty kidney tumour

No. Up to a third of small kidney masses turn out to be benign, and most kidney cancers that are picked up by chance on a scan are early and curable. An angiomyolipoma sits firmly on the benign side of that line: it is not a cancer, it is not a pre-cancer, and it does not travel to lymph nodes or to other organs. The wider picture of kidney tumours — types, stages and risk factors — is on our kidney cancer hub; this page stays with the angiomyolipoma itself.

What the name is telling you — the word is simply a description of what the growth is made of. Angio for blood vessels, myo for smooth muscle, lipoma for fat. All three are ordinary tissues that belong in the body anyway; in an angiomyolipoma they have grown together into a single lump inside or on the surface of the kidney. That is also why radiologists can often recognise one with real confidence: fat inside a kidney mass looks unmistakable on a CT or MRI, and it is one of the very few findings in kidney imaging that points close to a benign answer without a biopsy.

Why so many are being found now — not because they are new, but because scanning is. Ultrasound and CT are ordered every day for back pain, a suspected stone, abdominal discomfort or a routine health check, and they show the kidneys whether or not anyone was looking at them. Most angiomyolipomas are found exactly this way, in someone who had no symptoms at all and was being scanned for something else entirely. They are found more often in women, and most people who have one have a single tumour in one kidney.

So why does anyone follow it up? — because of bleeding, not because of cancer. The blood vessels inside an angiomyolipoma are abnormally formed, and can develop weak, balloon-like segments in their walls. In a small tumour this rarely matters. In a large one, or one that is steadily growing, there is a recognised risk that a vessel gives way and bleeds. Every piece of monitoring and every treatment decision described further down this page comes back to that single risk. It is worth being clear about, because it is easy to hear the word follow-up and assume somebody is quietly worried about cancer.

• Fat that is clearly visible on the scan. When a kidney mass plainly contains fat on CT or MRI, an angiomyolipoma is by far the most likely answer and the report will usually say so directly.
• The size of the tumour. Small ones are generally left alone. Larger ones are discussed — again because of bleeding risk, not because size makes them any more cancerous.
• Whether it has changed. A tumour that has clearly grown between two scans is looked at more closely than one that has been the same size for years.
• One, or several. Multiple angiomyolipomas, or tumours in both kidneys, prompt a wider assessment for an inherited condition rather than for cancer.
• Whether it contains too little fat to be sure. A minority are described as fat-poor. These cannot be confirmed on appearance alone, so they are worked up as an indeterminate kidney mass until they are properly characterised.

None of these findings means cancer — they decide how closely the tumour is watched. What does need urgent attention, angiomyolipoma or not, is sudden severe pain in the flank or side, especially with feeling faint or blood in the urine: that combination needs a hospital assessment straight away, not an outpatient appointment. For anything less alarming, book a free consultation and have your report read with you.

Most angiomyolipomas need no treatment at all. The question a specialist is actually answering is narrower than treat or don’t treat: it is whether this particular tumour, in this particular kidney, carries enough bleeding risk to be worth acting on rather than watching. Size, growth between scans, symptoms, how many tumours there are and how well the kidneys are working all feed into that. The table below sets out the common scenarios in plain English. It is a guide to what the words on a report tend to lead to — not a grading of your own scan.

This is a guide to terminology, not a grading of your own scan. Two reports using the same words can mean different things once the images are seen side by side.

How a diagnosis is actually confirmed — ultrasound almost always comes first, because it is quick, painless and radiation-free, and an angiomyolipoma often looks distinctly bright on it. Ultrasound alone cannot prove fat, so a dedicated contrast CT or an MRI follows to look for it properly and to see how the mass takes up contrast. Where a mass is fat-poor and the imaging cannot settle it, a biopsy is considered — but only when the result would genuinely change what happens next. At CION, ultrasound, contrast CT, MRI, biopsy and the blood and urine tests that run alongside them are all delivered in-house and read with you by a medical oncologist, not handed over as a report to interpret on your own. How CION separates a benign tumour from a malignant one, feature by feature, is set out in benign vs cancerous kidney tumours — how they are told apart.

What is done in-house at CION, and what is coordinated — the diagnostic pathway and the watching are ours. Active-surveillance monitoring, meaning the repeat scans and the clinic reviews for a tumour that is being followed, is run in-house so nobody drops off a follow-up list. Genetic counselling, where an inherited condition is in question, is in-house too. If a tumour does need a procedure, that is a different matter: embolisation to block the tumour’s blood supply, kidney-sparing surgery and ablation are coordinated for you with specialist interventional radiology, urology and uro-oncology partners at partner centres rather than performed in-house, and PET-CT, where it is ever needed, is arranged the same way. What each of those routes involves is set out on our kidney cancer treatment in Hyderabad page. The principle behind all of them is the same: keep as much working kidney tissue as possible, because the tumour being removed was never a cancer in the first place.

The inherited link, and where medicine comes in — a minority of angiomyolipomas are associated with tuberous sclerosis complex, an inherited condition that also causes benign growths in the skin, brain and other organs. It is suspected when the kidney tumours are multiple, affect both kidneys, appear at a younger age, or sit alongside the condition’s other features. That changes the plan: the assessment widens beyond the kidney, follow-up is closer, and a targeted medicine from the mTOR inhibitor class — which works by damping down the growth signalling that drives these tumours — is one recognised option. That is medical-oncology work and is delivered by our own team. Tuberous sclerosis, angiomyolipoma and kidney cancer goes through what the condition means for the kidneys and for the rest of the family.

Whichever route your report points to, the plan is not one doctor’s opinion. Any kidney mass with real uncertainty about it goes to CION’s tumour board — medical, surgical and radiation oncologists reviewing the images together, guided by NCCN recommendations for kidney cancer — and you are given the reasoning, in writing, before anything is arranged.

If your report used a particular word, start with the page that covers it directly.

• Tuberous sclerosis, angiomyolipoma & kidney cancer — when multiple angiomyolipomas point to an inherited condition, what it means for the kidneys, and what it means for the family.
• Benign vs cancerous kidney tumours — how they’re told apart — the features radiologists and oncologists actually use to separate the two, and where a fat-poor mass fits.
• Kidney cancer — the complete guide — types, stages, risk factors and symptoms, in one place.
• Kidney cancer treatment in Hyderabad — how treatment is planned at CION, what is delivered in-house, and what is coordinated with specialist partners.

Not sure which of these applies to you? Book a free consultation and ask an oncologist directly.

Get the wording on your report explained properly

Every uncertain case at CION goes to a tumour board, not one doctor’s opinion. If your angiomyolipoma needs nothing but a review date, we will tell you that plainly and send you home.

This page is general health information about angiomyolipoma of the kidney and how it is told apart from kidney cancer. It is not a diagnosis and it cannot replace a review of your own images. Only a doctor who has seen your scan and your history can say what your kidney mass is and what, if anything, it needs. If you have sudden severe pain in the flank or side, feel faint, or see blood in your urine, seek emergency care rather than waiting for a routine appointment.